JADE101 clinical trials
Also written JADE101.
How each study uses JADE101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the JADE101 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- JADE101
- 4
Studies by the year they started
4 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Jade Biosciences, Inc. (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test JADE101.
- May 2027A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese ParticipantsPhase 1 · Jade Biosciences, Inc.
Studies
Open first, then newest update. How each study uses JADE101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyRecruitingPhase 3Jade Biosciences, Inc.NCT07902817Written as JADE101
- A Study of JADE101 in Participants With Immunoglobulin A NephropathyRecruitingPhase 2Jade Biosciences, Inc.NCT07541287Written as JADE101
- A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese ParticipantsRecruitingPhase 1Jade Biosciences, Inc.NCT07525947Written as JADE101
- A Phase 1 Study of JADE101 in Healthy ParticipantsCompletedPhase 1Jade Biosciences, Inc.NCT07059312Written as JADE101
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting1
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyNov 3, 2026NCT07902817
Newly registered1
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyOct 29, 2026NCT07902817